- Conditions
- Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
- Interventions
- obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo
- Drug · Other
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 20
- States / cities
- Sun City West, Arizona • La Jolla, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced May 22, 2026, 5:46 AM EDT